![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the agreement with Cilcare to acquire the exclusive license to develop, manufacture, and commercialize CIL001 for the treatment of patients with hearing loss.
Lead Product(s): CIL001
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: CIL001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Shionogi
Deal Size: $16.0 million Upfront Cash: $16.0 million
Deal Type: Agreement June 10, 2024